Citi analyst Joanne Wuensch raised the firm’s price target on Edwards Lifesciences to $97 from $92 and keeps a Buy rating on the shares. Most Q4 results in medical technology met expectations, which bodes well for the sector, the analyst tells investors in a research note. The analyst says the group has historically "worked" in a beat and raise environment and historically has been "recessionary resistant."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on EW:
- Citi opens two positive, one negative catalyst watches in medical technology
- Edwards Lifesciences initiated with a Neutral at UBS
- Wells downgrades Edwards Lifesciences with Medtronic gaining share
- Edwards Lifesciences downgraded to Equal Weight from Overweight at Wells Fargo
- Bernstein medical tech/devices analysts hold analyst/industry conference call
